


Clinigen GAP Limited

Directors' Report and Unaudited Financial Statements

For the year ended 30 June 2018

AMENDED

Company Number: 07869194



Clinigen GAP Limited

Balance sheet at 30 June 2018

Company number 07869194	Note	2018 £	2017 £
Current assets			
Debtors	3	1	1
Net assets		1	1
Capital and reserves			
Called up share capital	4	1	1
Total shareholders' funds		1	1

Clinigen GAP Limited (the "Company") did not trade during either of the financial years under review and so no profit and loss account or statement of changes in total equity have been prepared. The Company has not received any income, incurred any expense or recognised any other gains or losses.

For the year ended 30 June 2018, the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies. The members have not required the Company to obtain an audit of its financial statements for the year ended 30 June 2018 in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These dormant company accounts replace the original "abridged" accounts filed on 4 July 2018 and are now the statutory accounts. They are prepared as they were at the date of the original accounts.

The financial statements on pages 1 and 2 were approved by the board and authorised for issue on 11 March 2019.



S Chilton
Director
On behalf of the board

Clinigen GAP Limited

Notes to the financial statements for the year ended 30 June 2018

1 Accounting policies

Basis of preparation of financial statements

These financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006 and UK Generally Accepted Accounting Practice (GAAP).

Reporting currency

These financial statements are presented in sterling, the Company's functional currency.

2 Profit and loss account and statement of comprehensive income

The Company did not trade during the current or prior year and accordingly no profit and loss account is presented. It had no other income or charges in either the current or prior year and accordingly no statement of comprehensive income is presented.

The Company had no employees during the current or prior year and accordingly no employee costs are included in these financial statements (2017: £nil). No directors received any remuneration in respect of their services to the Company (2017: £nil).

3 Debtors

	2018 £	2017 £
Amounts owed by group undertakings	1	1

The amounts owed by group undertakings are non-interest bearing and receivable on demand.

4 Share capital

	2018 £	2017 £
Issued, allotted, called up and fully paid 1 ordinary share of £1 each	1	1

5 Ultimate parent undertaking and controlling party

The Company is a wholly owned subsidiary undertaking of Clinigen Pharma Limited. The Company's ultimate parent undertaking and controlling party is Clinigen Group plc, a company registered in the United Kingdom.

Clinigen Group plc is the parent undertaking of the smallest and largest group of which the Company is a member. The consolidated financial statements of this group may be obtained from Pitcairn House, Crown Square, Centrum 100, Burton-on-Trent, Staffordshire, DE14 2WW.